STO · SPRINT.ST
Sprint Bioscience AB
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
Loading market information…
STO · SPAGO.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:23 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Spago Nanomedical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 80.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Spago Nanomedical AB (publ)’s next earnings report is currently expected on Nov 5, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Spago Nanomedical AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:18 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 459.00K |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
SEK 0.13+SEK 0.00 (+2.88%)
Simris Alg AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
SEK 16.70-SEK 0.20 (-1.18%)
Scandinavian Real Heart AB (Publ)’s quoted price sits in the lower half of its reported 52-week range, 29.54% below the high.
SEK 3.83+SEK 0.03 (+0.66%)
Active Biotech AB’s quoted price sits in the lower half of its reported 52-week range, 59.44% below the high.
SEK 1.57+SEK 0.01 (+0.32%)
Pila Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.4% below the high.
SEK 3.19-SEK 0.18 (-5.34%)
AcouSort AB’s quoted price sits in the lower half of its reported 52-week range, 38.18% below the high.
SEK 3.19+SEK 0.06 (+1.92%)
OncoZenge AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 68.97% below the high.
SEK 0.02+SEK 0.00 (+2.61%)
SpectraCure AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 93.5% below the high.
